Pei-Wei Yang , Su-Ping Ma , Xin-Ju Chen , Fang-Ming Yang , Shou-Mei Wang , Qian Wang , Shu-Hui Zhang
{"title":"木樨草素通过靶向miR-6809-5p/FLOT1/FAK并引发肝细胞癌中的EMT来抑制细胞迁移和侵袭","authors":"Pei-Wei Yang , Su-Ping Ma , Xin-Ju Chen , Fang-Ming Yang , Shou-Mei Wang , Qian Wang , Shu-Hui Zhang","doi":"10.1016/j.tranon.2025.102511","DOIUrl":null,"url":null,"abstract":"<div><div>Luteolin, 3′,4′,5,7-tetrahydroxyflavone, a natural flavonoid component found in various Chinese herbs such as Scutellaria barbata D. Don, honeysuckle, chrysanthemum, schizonepeta, and ajuga decumbens, exhibits potential for cancer prevention and therapy. This study elucidates the molecular mechanisms by which luteolin, an active constituent of Scutellaria barbata, inhibits invasion and metastasis of hepatocellular carcinoma (HCC) cell lines both in vitro and in vivo. The oncogenic microRNA miR-6809–5p was found to be aberrantly upregulated in HCC tissues and downregulated by luteolin in HCC cells; overexpression of miR-6809–5p was able to restore the anti-HCC effects of luteolin via the miR-6809–5p/FLOT1/FAK signaling pathway. Furthermore, luteolin suppressed HCC invasion, metastasis, and epithelial-mesenchymal transition (EMT) through modulation of the PI3K/AKT/mTOR pathway, affecting markers such as E-cadherin, β-catenin, Vimentin, N-cadherin, Snail, Twist, and Slug. This research demonstrates that luteolin effectively inhibits HCC cell migration and invasion and significantly suppresses epithelial mesenchymal transition (EMT) both in vitro and in vivo.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"61 ","pages":"Article 102511"},"PeriodicalIF":5.0000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Luteolin suppresses cell migration and invasion via targeting miR-6809-5p/FLOT1/FAK and eliciting EMT in hepatocellular carcinoma\",\"authors\":\"Pei-Wei Yang , Su-Ping Ma , Xin-Ju Chen , Fang-Ming Yang , Shou-Mei Wang , Qian Wang , Shu-Hui Zhang\",\"doi\":\"10.1016/j.tranon.2025.102511\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Luteolin, 3′,4′,5,7-tetrahydroxyflavone, a natural flavonoid component found in various Chinese herbs such as Scutellaria barbata D. Don, honeysuckle, chrysanthemum, schizonepeta, and ajuga decumbens, exhibits potential for cancer prevention and therapy. This study elucidates the molecular mechanisms by which luteolin, an active constituent of Scutellaria barbata, inhibits invasion and metastasis of hepatocellular carcinoma (HCC) cell lines both in vitro and in vivo. The oncogenic microRNA miR-6809–5p was found to be aberrantly upregulated in HCC tissues and downregulated by luteolin in HCC cells; overexpression of miR-6809–5p was able to restore the anti-HCC effects of luteolin via the miR-6809–5p/FLOT1/FAK signaling pathway. Furthermore, luteolin suppressed HCC invasion, metastasis, and epithelial-mesenchymal transition (EMT) through modulation of the PI3K/AKT/mTOR pathway, affecting markers such as E-cadherin, β-catenin, Vimentin, N-cadherin, Snail, Twist, and Slug. This research demonstrates that luteolin effectively inhibits HCC cell migration and invasion and significantly suppresses epithelial mesenchymal transition (EMT) both in vitro and in vivo.</div></div>\",\"PeriodicalId\":48975,\"journal\":{\"name\":\"Translational Oncology\",\"volume\":\"61 \",\"pages\":\"Article 102511\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1936523325002426\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523325002426","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Luteolin suppresses cell migration and invasion via targeting miR-6809-5p/FLOT1/FAK and eliciting EMT in hepatocellular carcinoma
Luteolin, 3′,4′,5,7-tetrahydroxyflavone, a natural flavonoid component found in various Chinese herbs such as Scutellaria barbata D. Don, honeysuckle, chrysanthemum, schizonepeta, and ajuga decumbens, exhibits potential for cancer prevention and therapy. This study elucidates the molecular mechanisms by which luteolin, an active constituent of Scutellaria barbata, inhibits invasion and metastasis of hepatocellular carcinoma (HCC) cell lines both in vitro and in vivo. The oncogenic microRNA miR-6809–5p was found to be aberrantly upregulated in HCC tissues and downregulated by luteolin in HCC cells; overexpression of miR-6809–5p was able to restore the anti-HCC effects of luteolin via the miR-6809–5p/FLOT1/FAK signaling pathway. Furthermore, luteolin suppressed HCC invasion, metastasis, and epithelial-mesenchymal transition (EMT) through modulation of the PI3K/AKT/mTOR pathway, affecting markers such as E-cadherin, β-catenin, Vimentin, N-cadherin, Snail, Twist, and Slug. This research demonstrates that luteolin effectively inhibits HCC cell migration and invasion and significantly suppresses epithelial mesenchymal transition (EMT) both in vitro and in vivo.
期刊介绍:
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.